Current financing round with a consortium of existing and new investors completed, bm-t beteiligungsmanagement thüringen gmbh increases lead investment
Erfurt/ Jena. SmartDyeLivery GmbH has successfully completed its most recent financing round in the mid-single-digit million range. In addition to bm-t beteiligungsmanagement thüringen gmbh (bm|t), which increased its lead investment, the Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT) and three new private investors invested in SmartDyeLivery´s development of innovative nanotherapies. The new group of private investors was formed with the support of the business angel and finance & M&A consultant Louis Moser from Munich/Grünwald, who again invested in the company.
SmartDyeLivery develops a platform technology for the targeted transport of active pharmaceutical ingredients. Based on functionalized nanotransporters, active substances are specifically delivered to affected organs of the body. "Our goal is to develop nanoparticles with high cell specificity in which drugs can be encapsulated in order to treat diseases in a more precise way, minimize or even entirely avoid side effects and ultimately save human lives," said Dr. Marc Lehmann, CEO of SmartDyeLivery. Especially in the context of the company´s first application of nanotransporters for a specific therapy for septic liver failure, the investment enables important development steps on the path to market approval.
About SmartDyeLivery: Jena-based SmartDyeLivery GmbH is developing a universal platform technology based on functionalized nanoparticles that can be used to transport active ingredients or other cargos to the desired site of action. The company´s aim is to provide new therapeutic options for diseases that have previously been untreatable or extremely difficult to treat. The innovative, patented technology can also be used for diagnostic or theragnostic applications.
Further information can be found at: www.smartdyelivery.de/en/
About bm|t: Erfurt-based bm|t is a subsidiary of the Thüringer Aufbaubank and the leading address for equity investments in Thüringen, Germany. bm|t currently manages nine funds with a total volume of around EUR 420 million, which invest in innovative companies across almost all sectors and in all phases of company development.
Further information about bm|t is available at: www.bm-t.com
About the STIFT: The STIFT supports, promotes and accompanies innovative technology-oriented and innovative business start-ups in Thüringen, Germany within the ThEx project. The STIFT also invests in selected high-tech start-ups as a co-investor. For its investment activities, the degree of innovation of the founding idea and the entrepreneurial potential form the main criteria.
Further information is available at: www.stift-thueringen.de
Dr. Marc Lehmann
Senior Investment Manager
bm-t beteiligungsmanagement thüringen gmbh
Erfurt/München/Jena. SmartDyeLivery has successfully completed its latest financing round. With its innovative nanotechnology for medical applications, the young company from Jena was able to acquire a business angel from Munich. bm-t beteiligungsmanagement thüringen gmbh also expanded its existing investment. "With the new growth capital, we are well positioned to reach the next stage in the development of our innovative therapy concept" says Dr. Marc Lehmann, CEO of SmartDyeLivery.
SmartDyeLivery develops functionalized nanoparticles that enclose active substances for targeted drug delivery directly into effected tissues or organs. The comprehensively patented system can be used for a broad range of applications in the field of therapy and enables a unique therapeutic approach due to its functionalisation. The SmartDyeLivery team is currently focusing on the therapy of septic liver failure with the aim of reducing the extremely high mortality rate of over 90%.
About bm|t: bm-t beteiligungsmanagement thüringen gmbh, based in Erfurt, is a subsidiary of the Thüringer Aufbaubank and the first address for investments in Thuringia. bm|t currently manages eight funds with a total invested volume of around €320 million, which invest in innovative companies in almost all sectors and in all phases of corporate development - both in the start-up and growth phases or in company succession situations. Further information about the bm|t can be found at sind verfügbar unter www.bm-t.de
Jena. medways e.V. - der Branchenverband Medizintechnik/Biotechnologie (industry association medical technology/biotechnology) is pleased to announce a new member: SmartDyeLivery GmbH from Jena develops functionalized nanoparticles for medical applications.
Innovative nanoparticles that find their way to the desired destination in the body by themselves and release the incorporated active ingredients only where they are needed – this is what SmartDyeLivery stands for. The patented functionalization of the particles with dyes acts like a navigation system in the body.
The team is currently focusing on a therapeutic application for septic liver failure. Due to a lack of therapy options, to the present day patients with this complication die in more than 90% of cases. Dr. Marc Lehmann, Managing Director, is convinced that "Our universal platform technology has the potential to offer more efficient treatment methods with less side-effects in the future and thus save lives". The advantage of the patented carrier platform is that it can be modularly adapted for further therapeutic areas. Numerous applications are also possible in the field of diagnostics and the increasingly important field of theranostics.
SmartDyeLivery is looking forward to benefiting from the medways service offerings in the future and trusts in a successful and fruitful cooperation.About medways e.V.- der Branchenverband Medizintechnik/Biotechnologie: Founded in 1999, medways has been a competent partner for almost 20 years for research projects, the approval of medical devices, the introduction of QM systems according to DIN EN ISO 13485 and further training of employees. In these fields, medways e.V. supports its member companies and partners with a wide range of services in the Service Center, Research Center and medways Academy functional units. Further information can be found at: www.medways.eu
Would you like to become a member of medways e.V.? Your contact person:
Erfurt / Jena. Using tiny particles to transport active substances into diseased organs of the body - this approach is pursued by the SmartDyeLivery GmbH from Jena. With the patented concept based on functionalized nanoparticles, SmartDyeLivery was able to convince the Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT), in addition to Sparkasse Jena-Saale-Holzland, which is further expanding its existing investment, and beteiligungsmanagement thüringen gmbh (bm|t), as a new investor in the Jena biotechnology company. Both the STIFT with the Board Members Professor Dr.-Ing. Werner Bornkessel and Dipl. Ing. Wolfgang Meyer and Managing Director Dr. Ing. Sven Günther as well as the Sparkasse Jena-Saale-Holzland with the Board Member Erhard Bückemeier and Investment Manager Tilo Mascher are convinced that this innovation from Thuringia, which can save lives, will be economically successful.
Nanoparticle-based technologies have great potential, especially in the medical sector. The SmartDyeLivery GmbH, in cooperation with the working groups around the founders and Jena university professors Ulrich S. Schubert and Michael Bauer, succeeded in developing nanoparticles that find their own way to the target in the body and release the transported active substances specifically and in a controlled manner only into the target cells. In addition to the specific transport of active agents, in the future, the function of affected organs will be determined with the help of nanoparticles. In a first area of application, the company is focusing on the development of a specific therapeutic for patients with septic liver failure. Because of the lack of treatment options, these patients die in more than 90% of cases. The new therapy option currently under development could save more than 1,500 lives a year in Germany alone. "The latest preclinical data demonstrate the enormous potential already in the first possible area of application and show that we are on the right path," says Dr. Marc Lehmann, Managing Director of the Jena-based biotechnology company.
Jena. The start-up company SmartDyeLivery GmbH became a partner of the InfectoGnostics Research Campus on March 1, 2016. Being a spin-off from the University Hospital and the Friedrich Schiller University Jena around Professors Michael Bauer and Prof. Ulrich S. Schubert, SmartDyeLivery develops and commercializes a universal technology platform for the cell type-specific transport of active substances with the help of functionalized nanoparticles.
"We are pleased to be able to participate in the InfectoGnostics Research Campus network in the future. Our platform is an ideal complement to InfectoGnostics' technology portfolio as it combines therapy and diagnostics in a so-called theranostic approach," said Dr. Marc Lehmann, CEO of SmartDyeLivery. "Combining the targeted and efficient administration of active ingredients that has less side-effects with a coordinated diagnostic approach is the ideal way to improve individualized patient care.”
Professor Jürgen Popp, CEO of InfectoGnostics, adds: "We are pleased to welcome the newly founded company SmartDyeLivery as a partner of the InfectoGnostics Research Campus. SmartDyeLivery's platform technology can be applied to a wide range of applications, such as special issues in the treatment of infections caused by antibiotic-resistant pathogens, which are at the heart of InfectoGnostics' campus project.
About Infectognostics - Forschungscampus Jena: The InfectoGnostics Research Campus Jena is a public-private partnership breaking new ground in the diagnosis of infections and pathogens such as viruses, bacteria and fungi. InfectoGnostics is funded by the BMBF as part of the "Research Campus - Public Private Partnership for Innovation" initiative with additional support from the state of Thuringia. Approximately half of the required budget is financed by the partners involved.
Erfurt/ Jena: To transport drugs and active substances only into diseased organs or cells of the body in a targeted manner and thus with fewer side effects – this is the approach of the SmartDyeLivery GmbH from Jena. The innovative concept convinced the bm-t beteiligungsmanagement thüringen gmbh (bm|t) and Sparkasse Jena-Saale-Holzland to jointly secure the start-up financing. The investors agree that a technological innovation in Thuringia that can save the lives of many people must be supported.
SmartDyeLivery GmbH is a spin-off of the Friedrich Schiller University and the Jena University Clinics around Professor Ulrich S. Schubert and Professor Michael Bauer. In preliminary projects funded by the Free State of Thuringia and the German government, the research team have succeeded in producing nanoparticles and loading them with active substances that are equipped with a navigation system, released specifically and in a controlled manner only where they are needed. It is particularly interesting that this "navigation system" can also be used for diagnostic purposes, such as the determination of organ function or the transport efficiency of particles.
In a first field of application, the company is focusing on the development of a specific therapeutic agent for patients with septic liver failure. Today, these patients die in more than 90% of cases. This high mortality rate is to be reduced by therapy options based on the innovative technology. In Germany alone, more than 1,500 lives could be saved every year. The managing directors Dr. Georg Hochwimmer and Dr. Marc Lehmann are firmly convinced that this platform technology can be used not only for the treatment of septic liver failure but also for a broad spectrum of other applications, e.g. in the field of cancer therapies.
About the bm|t: The bm|t beteiligungsmanagement thüringen GmbH, headquartered in Erfurt, is a subsidiary of the Thüringer Aufbaubank and one of the top addresses for investments in Thuringia. The bm|t currently manages nine funds with a total volume of around 340 million euros, which invest in innovative companies in almost all sectors and in all phases of corporate development, both in the start-up and growth phases or in company succession situations.
Investment Manager bm|t
Tel.: +49 361-7447-610
About the Sparkasse Jena-Saale-Holzland: The Sparkasse Jena-Saale-Holzland has been a strong and reliable partner in the Jena and Saale-Holzland region for more than 188 years. Thanks to the large branch network, the consultants are close to their customers and make important decisions quickly and directly on site. From the current account over real estate brokerage and mortgage lending to corporate and commercial customer support, the Sparkasse offers everything from one source. As a public-law institute, it is committed to the common good, economic development in the region and the people who live here.
Erfurt/Jena. SmartDyeLivery GmbH, a spin-off of the Friedrich Schiller University and the Jena University Clinics, was able to secure the highly endowed special prize for young companies as part of this year's Thuringia Innovation Award. In the coming years, the company will launch an innovative technology platform (patent pending) for the targeted transport of active substances into certain cells of the body. The active ingredient is transported with functionalized nanoparticles, tiny spheres that use dye molecules to navigate specifically to the diseased areas of the body, where they release their active ingredient in a controlled manner. The founding team led by Professor Ulrich S. Schubert from the Institute of Organic and Macromolecular Chemistry and Professor Michael Bauer, head of the Center for Sepsis Control and Care at the Clinic for Anaesthesiology and Intensive Care, is convinced that the technology will be successful in the future.
In a first field of application, the company is focusing on the development of a specific therapeutic for patients with septic liver failure. These patients die in more than 90% of cases, especially due to the current lack of specific treatment options. This high mortality rate is to be reduced by therapy options based on the award-winning technology. In Germany alone, more than 1,500 lives could be saved every year.
A high-ranking publication of the research results in the renowned scientific journal Nature Communications in December 2014 underlines the innovative approach that SmartDyeLivery is pursuing. The managing directors Dr. Georg Hochwimmer and Dr. Marc Lehmann, who are currently driving the development of the company, are firmly convinced that the technology can also be used for a broad spectrum of other application areas in addition to the treatment of septic liver failure, e.g. in the field of cancer therapies.